Three months ago, Charles Riv­er Lab­o­ra­to­ries an­nounced it would shed its man­u­fac­tur­ing unit, which has a fo­cus on cell and gene ther­a­pies. And, ac­cord­ing to...

WuXi Bi­o­log­ics has signed at least two new deals with no­table US biotechs so far this year, sig­nal­ing that the ser­vice provider con­tin­ues to emerge...

Af­ter three FDA re­jec­tions dat­ing back to 2023, Out­look Ther­a­peu­tics said the agency has re­versed course re­gard­ing its re­for­mu­lat­ed ver­sion of Avastin for the eye...

A key Re­pub­li­can con­gress­man asked the Trump ad­min­is­tra­tion to re­strict the stream of mon­ey in­to Chi­na’s biotech sec­tor, threat­en­ing to squelch the deal­mak­ing that’s be­come...

Gilead has at long last won US ap­proval of its he­pati­tis D treat­ment Hep­cludex, which the FDA pre­vi­ous­ly re­ject­ed over is­sues with its man­u­fac­tur­ing and...

Plus, news about Ag­i­lent’s earn­ings re­port:

☢️ Niowave’s ra­dioiso­tope fac­to­ry: The com­pa­ny has bro­ken groundon a $75 mil­lion pro­duc­tion fa­cil­i­ty in Lans­ing, MI, which...